Cimeio Therapeutics is an applied gene editing, cellular, and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs for patients with serious and life-threatening diseases. Cimeio’s proprietary technology platform is based on the discovery of protein variants, which when edited into cells allow them to maintain full function while resisting paired immunotherapy depletion. This technology has significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders.
Company Details
- Employees
- 19
- Founded
- 2020
- Address
- Cambridge, Ma, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.cimeio.com
- HQ
- Cambridge, MA
Cimeio Therapeutics Questions
Cimeio Therapeutics's website is http://www.cimeio.com
Cimeio Therapeutics's LinkedIn profile is https://www.linkedin.com/company/cimeio-therapeutics
Cimeio Therapeutics has
19 employees.
View email and phone details for 19
employees at Cimeio Therapeutics.
Cimeio Therapeutics's industry is
Biotechnology Research
Cimeio Therapeutics's top competitors are
Bright Peak Therapeutics,
Granite Bio,
Red Ridge Bio,
Monte Rosa Therapeutics,
Black Diamond Therapeutics,
Sixpeaks Bio,
Anaveon Ag,
Ridgeline Discovery,
Alentis Therapeutics,
Araris Biotech Ag.
Cimeio Therapeutics's categories are Biotechnology Research
Cimeio Therapeutics's founding year is 2020
